What is NON RARE IN EUROPE: Specific language impairment?
Specific Language Impairment (SLI), also known as Developmental Language Disorder (DLD), is a condition where children have significant difficulty learning and using language despite having normal hearing, normal intelligence, and no obvious neurological damage. It is not considered a rare disease in Europe, as it affects a substantial number of children. Children with SLI may struggle with putting words together into sentences, understanding what others say, finding the right words, or learning new vocabulary. Some children mainly have trouble with grammar, while others have broader difficulties across many areas of language. The condition typically becomes noticeable when a child is slower than expected to start talking or when their language skills fall noticeably behind those of other children the same age. SLI is believed to have a strong genetic component, meaning it often runs in families, though the exact pattern of inheritance is complex and involves multiple genes interacting with environmental factors. Speech and language therapy is the main form of treatment and can be very effective, especially when started early. While there is no medication that treats SLI directly, many children make significant progress with appropriate support. Some individuals continue to experience language difficulties into adulthood, but with the right strategies and accommodations, most people with SLI lead full and productive lives.
Key symptoms:
Late talking or slow to start speakingDifficulty forming sentences correctlyTrouble understanding what others sayLimited vocabulary for their ageDifficulty finding the right word during conversationProblems with grammar, such as leaving out small words or word endingsTrouble telling stories or explaining events in orderDifficulty following instructions, especially long or complex onesStruggling to learn new wordsProblems with reading and writing as they get olderDifficulty joining in conversations with other childrenTrouble understanding jokes, sarcasm, or figurative languageSocial difficulties related to communication challenges
- Inheritance
- Multifactorial
- Caused by a mix of several genes and environmental factors
- Age of Onset
- Childhood
- Begins in childhood, roughly ages 1 to 12
FDA & Trial Timeline
7 eventsHelsinki University Central Hospital — NA
Purdue University — NA
Purdue University — NA
Ohio State University — NA
IRCCS Eugenio Medea — NA
University of Delaware — NA
Father Flanagan's Boys' Home — NA
Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Specific language impairment.
7 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for NON RARE IN EUROPE: Specific language impairment.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to NON RARE IN EUROPE: Specific language impairment.
Community
No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Specific language impairment.
Start the conversation →Latest news about NON RARE IN EUROPE: Specific language impairment
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for NON RARE IN EUROPE: Specific language impairment.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific areas of language is my child struggling with the most?,How often should my child receive speech-language therapy, and what type is recommended?,What can I do at home to support my child's language development?,Should my child be tested for hearing problems or other conditions?,What school accommodations should I request for my child?,Is my child at risk for reading or learning difficulties later on?,Could this run in our family, and should other children be assessed?
Common questions about NON RARE IN EUROPE: Specific language impairment
What is NON RARE IN EUROPE: Specific language impairment?
Specific Language Impairment (SLI), also known as Developmental Language Disorder (DLD), is a condition where children have significant difficulty learning and using language despite having normal hearing, normal intelligence, and no obvious neurological damage. It is not considered a rare disease in Europe, as it affects a substantial number of children. Children with SLI may struggle with putting words together into sentences, understanding what others say, finding the right words, or learning new vocabulary. Some children mainly have trouble with grammar, while others have broader difficul
How is NON RARE IN EUROPE: Specific language impairment inherited?
NON RARE IN EUROPE: Specific language impairment follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does NON RARE IN EUROPE: Specific language impairment typically begin?
Typical onset of NON RARE IN EUROPE: Specific language impairment is childhood. Age of onset can vary across affected individuals.
Are there clinical trials for NON RARE IN EUROPE: Specific language impairment?
Yes — 7 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Specific language impairment on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Frequently asked questions about NON RARE IN EUROPE: Specific language impairment
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is NON RARE IN EUROPE: Specific language impairment?
NON RARE IN EUROPE: Specific language impairment is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:458713). It is typically inherited as multifactorial. Age of onset is generally childhood. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Specific language impairment page.
How is NON RARE IN EUROPE: Specific language impairment inherited?
NON RARE IN EUROPE: Specific language impairment follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for NON RARE IN EUROPE: Specific language impairment?
Approved treatments for NON RARE IN EUROPE: Specific language impairment are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials recruiting for NON RARE IN EUROPE: Specific language impairment?
UniteRare currently lists 7 clinical trials relevant to NON RARE IN EUROPE: Specific language impairment sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.
How do I find a specialist for NON RARE IN EUROPE: Specific language impairment?
Verified NON RARE IN EUROPE: Specific language impairment specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full NON RARE IN EUROPE: Specific language impairment page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.